Epoetin Zeta Drug Aliquot | Anti-EPO receptor | Therapeutic Glycoprotein Hormone

Aliquoted from the biosimilar drug | Now available for research use

Aliquots of the biosimilar Epoetin Zeta are now available as research consumables.

Epoetin Zeta drug aliquots can be used for in vitro or in vivo experiments. Several other reference drugs are also available. The drug aliquots are generated by aliquoting (dividing and repackaging) the EU-licensed reference drug.

Not looking for Epoetin Zeta Biosimilar Drug?

Search our therapeutic molecules product database

Quick Ordering

Find and order your therapeutic molecules through smart filters

Multiple Batches

Up to 10 batches of original drugs for examining batch-to-batch variations

Reduce Costs

Up to 80% less compared to the original pharmaceutical price

Worldwide Shipping

Shipment within days worldwide according to GDP-standards

Precise Quantity​​

Up to 80% less compared to the original pharmaceutical price

Silapo® / Epoetin zeta Biosimilar Drug

Drug nameSilapo®
INNEpoetin zeta
API typeGlycoprotein hormone
Pharmacotherapeutic group
Other antianaemic preparations, erythropoietin
ATC code
Target of antibody
Erythropoietin cell surface receptors
General functionEpoetin zeta is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (CRF)
Short description
Pharmacodynamic properties
(Mechanism of action; Source EMA document)
Epoetin zeta is a biosimilar medicinal product. Erythropoietin (EPO) is a glycoprotein hormone produced primarily by the kidney in response to hypoxia and is the key regulator of RBC production. EPO is involved in all phases of erythroid development, and has its principal effect at the level of erythroid precursors. After EPO binds to its cell surface receptor, it activates signal transduction pathways that interfere with apoptosis and stimulates erythroid cell proliferation. Recombinant human EPO (epoetin zeta), expressed in Chinese hamster ovary cells, has a 165 amino acid sequence identical to that of human urinary EPO; the 2 are indistinguishable on the basis of functional assays. The apparent molecular weight of erythropoietin is 32 000 to 40 000 dalton
Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document)After single doses (20 000 to 160 000 IU subcutaneously) of epoetin alfa, a dose-dependent response was observed for the pharmacodynamic markers investigated including: reticulocytes, RBCs, and haemoglobin.
Original license holder
Stada Arzneimittel AG
Marketing authorisation numbers
EU/1/07/432/001- EU/1/07/432/047
Marketing authorisation holder
STADA Arzneimittel AG

Stadastrasse 2-18

D-61118 Bad Vilbel

Name of the manufacturer of the biological active substance
Norbitec GmbH Pinnauallee 4 D-25436 Uetersen Germany
Name and address of the manufacturer(s) responsible for batch releaseSTADA Arzneimittel AG Stadastrasse 2-18 D-61118 Bad Vilbel Germany
Max shelf life
30 months
Storage conditions
2°C – 8°C
List of excipients
Disodium phosphate dihydrate, Sodium dihydrogen phosphate dihydrate, Sodium chloride, Calcium chloride dihydrate, Polysorbate 20, Glycine, Leucine, Isoleucine ,Threonine, Glutamic acid, Phenylalanine, Sodium hydroxide (pH adjuster), Hydrochloric acid (pH adjuster).
Contains phenylalanine.

Evidentic – fast, accurate, secure

Our products are empowering researchers worldwide​

Evidentic offers multiple batches of original drug aliquots in low binding Eppendorf tubes for research use only. We provide licence-free drug aliquots with long, short or even “negative shelf life” by storing the products at recommended temperatures (either 2-8°C or -80°C) and ensuring fully functional molecules for research purposes.